AVLNAvalyn Pharma Inc.
$25.70
$25.70
$25.3752 weeks$39.39
Price
End-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for AVLN today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$1.28B
1 yearn/a
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 11, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 16, 2026Appointment of Director On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Avalyn Pharma Inc. (the “Company”), the Board appointed Robert Meyer, M.D. to the Board as a Class II director for an initial …Director or officer change · Form 8-K
- Aug 12, 2026Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- Jul 1, 2026On June 29, 2026 (the “Effective Date”), Avalyn Pharma Inc. (the “Company”) entered into a First Amendment to the Sublease (the “Sublease Amendment”), which amends that certain Sublease Agreement (the “Sublease Agreement”) with CRISPR Therapeutics, Inc. (the “Sublandlord”), dated as of August 29, 2025, providing for …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
On our screens:Stocks with no debt
Biotechnology
The closest names by size in the same industry